Arenaviruses and lethal mutagenesis. prospects for new ribavirin-based interventions

Viruses

Volumn 4, Issue 11, 2012, Pages 2786-2805

  Moreno, Héctor ^a   Grande Pérez, Ana ^b   Domingo, Esteban ^a,c   Martín, Verónica ^d  

^a CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

^b UNIVERSITY OF MÁLAGA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria Consejo Superior de Investigaciones Científicas   (Spain)

Author keywords

5 fluorouracil; Antiviral treatment; Lymphocytic choriomeningitis virus; Viral quasispecies

Indexed keywords

FLUOROURACIL; RIBAVIRIN; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARENAVIRUS; ARENAVIRUS INFECTION; CONCENTRATION RESPONSE; DRUG DESIGN; LETHAL MUTAGENESIS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MUTAGENESIS; NONHUMAN; REVIEW; RNA REPLICATION; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; ARENAVIRIDAE INFECTIONS; ARENAVIRUS; DRUG THERAPY, COMBINATION; GENES, LETHAL; GENES, VIRAL; HUMANS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MUTAGENESIS; MUTATION; RIBAVIRIN;

ARENAVIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS;

EID: 84870603707     PISSN: 19994915     EISSN: None     Source Type: Journal    
DOI: 10.3390/v4112786     Document Type: Review

References (102)

1. Oldstone, M.B.A. Arenaviruses I and III. Current Topics in Microbiol. and Immunol: Berlin, Heidelberg, 2002; Vol. 262 and 263. Springer-Verlag.
2. Buchmeier, M.J.; de la Torre, J.C.; Peters, C.J. Arenaviridae: the viruses and their replication. D.M. Knipe, P.M. Howley, et al. Eds. Lappincott Williams & Wilkins: Phyladelphia, 2007; pp. 1791-1827.
3. Briese, T.; Paweska, J.T.; McMullan, L.K.; Hutchison, S.K.; Street, C.; Palacios, G.; Khristova, M.L.; Weyer, J.; Swanepoel, R.; Egholm, M.; Nichol, S.T.; Lipkin, W.I. Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa. PLoS Pathog. 2009, 5, e1000455.
4. Goeijenbier, M.; Wagenaar, J.; Goris, M.; Martina, B.; Henttonen, H.; Vaheri, A.; Reusken, C.; Hartskeerl, R.; Osterhaus, A.; Van Gorp, E. Rodent-borne hemorrhagic fevers: under-recognized, widely spread and preventable-epidemiology, diagnostics and treatment. Critical reviews in microbiology 2012, in press.
5. Barton, L.L. Lymphocytic choriomeningitis virus: a neglected central nervous system pathogen. Clin. Infect. Dis. 1996, 22, 197.
6. Fischer, S.A.; Graham, M.B.; Kuehnert, M.J.; Kotton, C.N.; Srinivasan, A.; Marty, F.M.; Comer, J.A.; Guarner, J.; Paddock, C.D.; DeMeo, D.L.; Shieh, W.J.; Erickson, B.R.; Bandy, U.; DeMaria, A., Jr.; Davis, J.P.; Delmonico, F.L.; Pavlin, B.; Likos, A.; Vincent, M.J.; Sealy, T.K.; Goldsmith, C.S.; Jernigan, D.B.; Rollin, P.E.; Packard, M.M.; Patel, M.; Rowland, C.; Helfand, R.F.; Nichol, S.T.; Fishman, J.A.; Ksiazek, T.; Zaki, S.R. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N. Engl. J. Med. 2006, 354, 2235-2249.
7. Jamieson, D.J.; Kourtis, A.P.; Bell, M.; Rasmussen, S.A. Lymphocytic choriomeningitis virus: an emerging obstetric pathogen? Am. J. Obstet. Gynecol. 2006, 194(6), 1532-1536.
8. Palacios, G.; Druce, J.; Du, L.; Tran, T.; Birch, C.; Briese, T.; Conlan, S.; Quan, P.L.; Hui, J.; Marshall, J.; Simons, J.F.; Egholm, M.; Paddock, C.D.; Shieh, W.J.; Goldsmith, C.S.; Zaki, S.R.; Catton, M.; Lipkin, W.I. A new arenavirus in a cluster of fatal transplant-associated diseases. N. Engl. J. Med. 2008, 358, 991-998.
9. Ambrosio, A.; Saavedra, M.; Mariani, M.; Gamboa, G.; Maiza, A. Argentine hemorrhagic fever vaccines. Human vaccines 2011, 7, 694-700.
10. Goicochea, M.A.; Zapata, J.C.; Bryant, J.; Davis, H.; Salvato, M.S.; Lukashevich, I.S. Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model. Vaccine 2012, 30, 1445-1452.
11. Sepulveda, C.S.; Garcia, C.C.; Fascio, M.L.; D'Accorso, N.B.; Docampo Palacios, M.L.; Pellon, R.F.; Damonte, E.B. Inhibition of Junin virus RNA synthesis by an antiviral acridone derivative. Antiviral. Res. 2012, 93, 16-22.
12. Mendenhall, M.; Russell, A.; Smee, D.F.; Hall, J.O.; Skirpstunas, R.; Furuta, Y.; Gowen, B.B. Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic Fever. PLoS neglected tropical diseases 2011, 5, e1342.
13. Gowen, B.B.; Smee, D.F.; Wong, M.H.; Hall, J.O.; Jung, K.H.; Bailey, K.W.; Stevens, J.R.; Furuta, Y.; Morrey, J.D. Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS One 2008, 3, e3725.
14. McCormick, J.B.; King, I.J.; Webb, P.A.; Scribner, C.L.; Craven, R.B.; Johnson, K.M.; Elliott, L.H.; Belmont-Williams, R. Lassa fever. Effective therapy with ribavirin. N. Engl. J. Med. 1986, 314, 20-26.
15. Domingo, E.; Sheldon, J.; Perales, C. Viral quasispecies evolution. Microbiology and Molecular Biology Reviews 2012, 76, 159-216.
16. Jabara, C.B.; Jones, C.D.; Roach, J.; Anderson, J.A.; Swanstrom, R. Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc. Natl. Acad. Sci. USA 2011, 108, 20166-20171.
17. Fernandez, G.; Clotet, B.; Martinez, M.A. Fitness landscape of human immunodeficiency virus type 1 protease quasispecies. J. Virol. 2007, 81, 2485-2496.
18. Ciurea, A.; Klenerman, P.; Hunziker, L.; Horvath, E.; Senn, B.M.; Ochsenbein, A.F.; Hengartner, H.; Zinkernagel, R.M. Viral persistence in vivo through selection of neutralizing antibody-escape variants. Proc. Natl. Acad. Sci. USA 2000, 97, 2749-2754.
19. Aebischer, T.; Moskophidis, D.; Rohrer, U.H.; Zinkernagel, R.M.; Hengartner, H. In vitro selection of lymphocytic choriomeningitis virus escape mutants by cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA 1991, 88, 11047-11051.
20. Ahmed, R.; Hahn, C.S.; Somasundaram, T.; Villarete, L.; Matloubian, M.; Strauss, J.H. Molecular basis of organ-specific selection of viral variants during chronic infection. J. Virol. 1991, 65, 4242-4247.
21. Ahmed, R.; Simon, R.S.; Matloubian, M.; Kolhekar, S.R.; Southern, P.J.; Freedman, D.M. Genetic analysis of in vivo-selected viral variants causing chronic infection: importance of mutation in the L RNA segment of lymphocytic choriomeningitis virus. J. Virol. 1988, 62, 3301-3308.
22. Buesa-Gomez, J.; Teng, M.N.; Oldstone, C.E.; Oldstone, M.B.; de la Torre, J.C. Variants able to cause growth hormone deficiency syndrome are present within the disease-nil WE strain of lymphocytic choriomeningitis virus. J. Virol. 1996, 70, 8988-8992.
23. Ciurea, A.; Hunziker, L.; Martinic, M.M.; Oxenius, A.; Hengartner, H.; Zinkernagel, R.M. CD4+ T-cell-epitope escape mutant virus selected in vivo. Nat. Med. 2001, 7, 795-800.
24. Dockter, J.; Evans, C.F.; Tishon, A.; Oldstone, M.B. Competitive selection in vivo by a cell for one variant over another: implications for RNA virus quasispecies in vivo. J. Virol. 1996, 70, 1799-1803.
25. Evans, C.F.; Borrow, P.; de la Torre, J.C.; Oldstone, M.B. Virus-induced immunosuppression: kinetic analysis of the selection of a mutation associated with viral persistence. J. Virol. 1994, 68, 7367-7373.
26. Matloubian, M.; Kolhekar, S.R.; Somasundaram, T.; Ahmed, R. Molecular determinants of macrophage tropism and viral persistence: importance of single amino acid changes in the polymerase and glycoprotein of lymphocytic choriomeningitis virus. J. Virol. 1993, 67, 7340-7349.
27. Matloubian, M.; Somasundaram, T.; Kolhekar, S.R.; Selvakumar, R.; Ahmed, R. Genetic basis of viral persistence: single amino acid change in the viral glycoprotein affects ability of lymphocytic choriomeningitis virus to persist in adult mice. J. Exp. Med. 1990, 172, 1043-1048.
28. Pircher, H.; Moskophidis, D.; Rohrer, U.; Burki, K.; Hengartner, H.; Zinkernagel, R.M. Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo. Nature 1990, 346, 629-633.
29. Salvato, M.; Borrow, P.; Shimomaye, E.; Oldstone, M.B. Molecular basis of viral persistence: a single amino acid change in the glycoprotein of lymphocytic choriomeningitis virus is associated with suppression of the antiviral cytotoxic T-lymphocyte response and establishment of persistence. J. Virol. 1991, 65, 1863-1869.
30. Teng, M.N.; Borrow, P.; Oldstone, M.B.; de la Torre, J.C. A single amino acid change in the glycoprotein of lymphocytic choriomeningitis virus is associated with the ability to cause growth hormone deficiency syndrome. J. Virol. 1996, 70, 8438-8443.
31. Hunziker, L.; Ciurea, A.; Recher, M.; Hengartner, H.; Zinkernagel, R.M. Public versus personal serotypes of a viral quasispecies. Proc. Natl. Acad. Sci. USA 2003, 100, 6015-6020.
32. Teng, M.N.; Oldstone, M.B.; de la Torre, J.C. Suppression of lymphocytic choriomeningitis virus-induced growth hormone deficiency syndrome by disease-negative virus variants. Virology 1996, 223, 113-119.
33. Sevilla, N.; Domingo, E.; de la Torre, J.C. Contribution of LCMV towards deciphering biology of quasispecies in vivo. Curr. Top. Microbiol. Immunol. 2002, 263, 197-220.
34. Sevilla, N.; de la Torre, J.C., Arenavirus Diversity And Evolution: Quasispecies In Vivo. In Cur. Top. Microbiol. Immunol. 2006; Vol. 299, pp 315-335.
35. Grande-Pérez, A.; Sierra, S.; Castro, M.G.; Domingo, E.; Lowenstein, P.R. Molecular indetermination in the transition to error catastrophe: systematic elimination of lymphocytic choriomeningitis virus through mutagenesis does not correlate linearly with large increases in mutant spectrum complexity. Proc. Natl. Acad. Sci. USA 2002, 99, 12938-12943.
36. Grande-Pérez, A.; Gómez-Mariano, G.; Lowenstein, P.R.; Domingo, E. Mutagenesis-induced, large fitness variations with an invariant arenavirus consensus genomic nucleotide sequence. J. Virol. 2005, 79, 10451-10459.
37. Ruiz-Jarabo, C.M.; Ly, C.; Domingo, E.; de la Torre, J.C. Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology 2003, 308, 37-47.
38. Martin, V.; Abia, D.; Domingo, E.; Grande-Perez, A. An interfering activity against lymphocytic choriomeningitis virus replication associated with enhanced mutagenesis. J. Gen. Virol. 2010, 91, 990-1003.
39. Moreno, H.; Gallego, I.; Sevilla, N.; de la Torre, J.C.; Domingo, E.; Martin, V. Ribavirin can be mutagenic for arenaviruses. J. Virol. 2011, 85, 7246-7255.
40. Moreno, H.; Tejero, H.; de la Torre, J.C.; Domingo, E.; Martin, V. Mutagenesis-mediated virus extinction: virus-dependent effect of viral load on sensitivity to lethal defection. PLoS One 2012, 7, e32550.
41. Graci, J.D.; Cameron, C.E. Therapeutically targeting RNA viruses via lethal mutagenesis. Future Virol. 2008, 3, 553-566.
42. Eigen, M.; Schuster, P. The hypercycle. A principle of natural self-organization. Springer: Berlin, 1979.
43. Biebricher, C.K.; Eigen, M. The error threshold. Virus Res. 2005, 107, 117-127.
44. Clay, P.G.; McRae, M.; Laurent, J.P. Safety, Tolerability, and Pharmacokinetics of KP-1461 in Phase I Clinical Studies: A Single Oral Dose Study in Non-HIV-Infected Adults, and a 14-Day Dose-Escalating Study in Highly Antiretroviral-Experienced HIV-Infected Adults. J. Int. Assoc. Physicians AIDS Care (Chic) 2011, 10, 232-238.
45. Harris, K.S.; Brabant, W.; Styrchak, S.; Gall, A.; Daifuku, R. KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis. Antiviral Res. 2005, 67, 1-9.
46. Hicks, C.; Clay, P.; Redfield, R.; Lalezari, J.; Liporace, R.; Schneider, S.; Sension, M.; McRae, M.; Laurent, J.P. Safety, Tolerability, and Efficacy of KP-1461 as Monotherapy for 124 Days in Antiretroviral-Experienced, HIV Type 1-Infected Subjects. AIDS research and human retroviruses 2012, in press.
47. Harki, D.A.; Graci, J.D.; Edathil, J.P.; Castro, C.; Cameron, C.E.; Peterson, B.R. Synthesis of a universal 5-nitroindole ribonucleotide and incorporation into RNA by a viral RNA-dependent RNA polymerase. Biochemistry 2007, 8, 1359-1362.
48. Harki, D.A.; Graci, J.D.; Galarraga, J.E.; Chain, W.J.; Cameron, C.E.; Peterson, B.R. Synthesis and antiviral activity of 5-substituted cytidine analogues: identification of a potent inhibitor of viral RNA-dependent RNA polymerases. J. Med. Chem. 2006, 49, 6166-6169.
49. Harki, D.A.; Graci, J.D.; Korneeva, V.S.; Ghosh, S.K.; Hong, Z.; Cameron, C.E.; Peterson, B.R. Synthesis and antiviral evaluation of a mutagenic and non-hydrogen bonding ribonucleoside analogue: 1-beta-D-Ribofuranosyl-3-nitropyrrole. Biochemistry 2002, 41, 9026-9033.
50. Chu, C.K., Recent advances in nucleosides: Chemistry. and chemotherapy. Amsterdam: Elsevier: 2002.
51. Mullins, J.I.; Heath, L.; Hughes, J.P.; Kicha, J.; Styrchak, S.; Wong, K.G.; Rao, U.; Hansen, A.; Harris, K.S.; Laurent, J.P.; Li, D.; Simpson, J.H.; Essigmann, J.M.; Loeb, L.A.; Parkins, J. Mutation of HIV-1 genomes in a clinical population treated with the mutagenic nucleoside KP1461. PLoS One 2011, 6, e15135.
52. Scheidel, L.M.; Durbin, R.K.; Stollar, V. Sindbis virus mutants resistant to mycophenolic acid and ribavirin. Virology 1987, 158, 1-7.
53. Scheidel, L.M.; Stollar, V. Mutations that confer resistance to mycophenolic acid and ribavirin on Sindbis virus map to the nonstructural protein nsP1. Virology 1991, 181, 490-499.
54. Rosenblum, C.I.; Stollar, V. SVMPA, a mutant of sindbis virus resistant to mycophenolic acid and ribavirin, shows an increased sensitivity to chick interferon. Virology 1999, 259, 228-233.
55. Agudo, R.; Ferrer-Orta, C.; Arias, A.; de la Higuera, I.; Perales, C.; Perez-Luque, R.; Verdaguer, N.; Domingo, E. A multi-step process of viral adaptation to a mutagenic nucleoside analogue by modulation of transition types leads to extinction-escape. PLoS Pathog. 2010, 6, e1001072.
56. Pfeiffer, J.K.; Kirkegaard, K. A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc. Natl. Acad. Sci. USA 2003, 100, 7289-7294.
57. Pfeiffer, J.K.; Kirkegaard, K. Increased fidelity reduces poliovirus fitness under selective pressure in mice. PLoS Pathog. 2005, 1, 102-110.
58. Vignuzzi, M.; Stone, J.K.; Arnold, J.J.; Cameron, C.E.; Andino, R. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 2006, 439, 344-348.
59. Arias, A.; Arnold, J.J.; Sierra, M.; Smidansky, E.D.; Domingo, E.; Cameron, C.E. Determinants of RNA-dependent RNA polymerase (in)fidelity revealed by kinetic analysis of the polymerase encoded by a foot-and-mouth disease virus mutant with reduced sensitivity to ribavirin. J. Virol. 2008, 82, 12346-12355.
60. Ferrer-Orta, C.; Sierra, M.; de la Higuera, I.; Agudo, R.; Arias, A.; Perez-Luque, R.; Escarmis, C.; Domingo, E.; Verdaguer, N. Structure of foot-and-mouth disease virus mutant polymerases with reduced sensitivity to ribavirin. J. Virol. 2010, 84, 6188-6199.
61. Sierra, M.; Airaksinen, A.; González-López, C.; Agudo, R.; Arias, A.; Domingo, E. Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe. J. Virol. 2007, 81, 2012-2024.
62. Feigelstock, D.A.; Mihalik, K.B.; Feinstone, S.M. Selection of hepatitis C virus resistant to ribavirin. Virology journal 2011, 8, 402.
63. Coffey, L.L.; Beeharry, Y.; Borderia, A.V.; Blanc, H.; Vignuzzi, M. Arbovirus high fidelity variant loses fitness in mosquitoes and mice. Proc. Natl. Acad. Sci. USA 2011, 108, 16038-16043.
64. Pfeiffer, J.K.; Kirkegaard, K. Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA. J. Virol. 2005, 79, 2346-2355.
65. Levi, L.I.; Gnadig, N.F.; Beaucourt, S.; McPherson, M.J.; Baron, B.; Arnold, J.J.; Vignuzzi, M. Fidelity variants of RNA dependent RNA polymerases uncover an indirect, mutagenic activity of amiloride compounds. PLoS Pathog. 2010, 6, e1001163.
66. Young, K.C.; Lindsay, K.L.; Lee, K.J.; Liu, W.C.; He, J.W.; Milstein, S.L.; Lai, M.M. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hepatology 2003, 38, 869-878.
67. Grande-Pérez, A.; Lazaro, E.; Lowenstein, P.; Domingo, E.; Manrubia, S.C. Suppression of viral infectivity through lethal defection. Proc. Natl. Acad. Sci. USA 2005, 102, 4448-4452.
68. Eigen, M. Error catastrophe and antiviral strategy. Proc. Natl. Acad. Sci. USA 2002, 99, 13374-13376.
69. Holland, J.J.; Domingo, E.; de la Torre, J.C.; Steinhauer, D.A. Mutation frequencies at defined single codon sites in vesicular stomatitis virus and poliovirus can be increased only slightly by chemical mutagenesis. J. Virol. 1990, 64, 3960-3962.
70. Loeb, L.A.; Essigmann, J.M.; Kazazi, F.; Zhang, J.; Rose, K.D.; Mullins, J.I. Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc. Natl. Acad. Sci. USA 1999, 96, 1492-1497.
71. Sierra, S.; Dávila, M.; Lowenstein, P.R.; Domingo, E. Response of foot-and-mouth disease virus to increased mutagenesis. Influence of viral load and fitness in loss of infectivity. J. Virol. 2000, 74, 8316-8323.
72. Crotty, S.; Maag, D.; Arnold, J.J.; Zhong, W.; Lau, J.Y.N.; Hong, Z.; Andino, R.; Cameron, C.E. The broad-spectrum antiviral ribonucleotide, ribavirin, is an RNA virus mutagen. Nature Medicine 2000, 6, 1375-1379.
73. Perales, C.; Agudo, R.; Tejero, H.; Manrubia, S.C.; Domingo, E. Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infections. PLoS Pathog. 2009, 5, e1000658.
74. Perales, C.; Iranzo, J.; Manrubia, S.C.; Domingo, E. The impact of quasispecies dynamics on the use of therapeutics. Trends in microbiology 2012, in press.
75. Iranzo, J.; Perales, C.; Domingo, E.; Manrubia, S.C. Tempo and mode of inhibitor-mutagen antiviral therapies: A multidisciplinary approach. Proc. Natl. Acad. Sci. USA 2011, 108, 16008-16013.
76. Dapp, M.J.; Clouser, C.L.; Patterson, S.; Mansky, L.M. 5-Azacytidine can induce lethal mutagenesis in human immunodeficiency virus type 1. J. Virol. 2009, 83, 11950-11958.
77. Iranzo, J.; Manrubia, S.C. Stochastic extinction of viral infectivity through the action of defectors. Europhys. Lett. 2009, 85, 18001.
78. Turner, P.E.; Chao, L. Prisoner's dilemma in an RNA virus. Nature 1999, 398, 441-443.
79. Wilke, C.O.; Reissig, D.D.; Novella, I.S. Replication at periodically changing multiplicity of infection promotes stable coexistence of competing viral populations. Evolution Int. J. Org. Evolution 2004, 58, 900-905.
80. Perales, C.; Mateo, R.; Mateu, M.G.; Domingo, E. Insights into RNA virus mutant spectrum and lethal mutagenesis events: replicative interference and complementation by multiple point mutants. J. Mol. Biol. 2007, 369, 985-1000.
81. Youngner, J.S.; Whitaker-Dowling, P. Interference. In Encyclopedia of Virology, Granoff, A.; Webster, R.G., Eds. Academic Press: San Diego, California, 1999; Vol. 2, pp 850-854.
82. de la Torre, J.C.; Holland, J.J. RNA virus quasispecies populations can suppress vastly superior mutant progeny. J. Virol. 1990, 64, 6278-6281.
83. Chumakov, K.M.; Powers, L.B.; Noonan, K.E.; Roninson, I.B.; Levenbook, I.S. Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine. Proc. Natl. Acad. Sci. USA 1991, 88, 199-203.
84. Crowder, S.; Kirkegaard, K. Trans-dominant inhibition of RNA viral replication can slow growth of drug-resistant viruses. Nature Genetics 2005, 37, 701-709.
85. González-López, C.; Arias, A.; Pariente, N.; Gómez-Mariano, G.; Domingo, E. Preextinction viral RNA can interfere with infectivity. J. Virol. 2004, 78, 3319-3324.
86. Perales, C.; Lorenzo-Redondo, R.; López-Galíndez, C.; Martínez, M.A.; Domingo, E. Mutant spectra in virus behavior. Future Virology 2010, 5, 679-698.
87. Ojosnegros, S.; Perales, C.; Mas, A.; Domingo, E. Quasispecies as a matter of fact: viruses and beyond. Virus. Res. 2011, 162, 203-215.
88. Xiang, D.; Sharma, V.R.; Freter, C.E.; Yan, J. Anti-tumor Monoclonal Antibodies in Conjunction with beta-Glucans: a Novel Anti-cancer Immunotherapy. Current medicinal chemistry 2012, in press.
89. Murphy, C.G.; Morris, P.G. Recent advances in novel targeted therapies for HER2-positive breast cancer. Anti-cancer drugs 2012, 23, 765-776.
90. Pariente, N.; Sierra, S.; Lowenstein, P.R.; Domingo, E. Efficient virus extinction by combinations of a mutagen and antiviral inhibitors. J. Virol. 2001, 75, 9723-9730.
91. Tapia, N.; Fernandez, G.; Parera, M.; Gomez-Mariano, G.; Clotet, B.; Quinones-Mateu, M.; Domingo, E.; Martinez, M.A. Combination of a mutagenic agent with a reverse transcriptase inhibitor results in systematic inhibition of HIV-1 infection. Virology 2005, 338, 1-8.
92. Agudo, R.; Arias, A.; Pariente, N.; Perales, C.; Escarmis, C.; Jorge, A.; Marina, A.; Domingo, E. Molecular characterization of a dual inhibitory and mutagenic activity of 5-fluorouridine triphosphate on viral RNA synthesis. Implications for lethal mutagenesis. J. Mol. Biol. 2008, 382, 652-666.
93. Perales, C.; Agudo, R.; Domingo, E. Counteracting quasispecies adaptability: extinction of a ribavirin-resistant virus mutant by an alternative mutagenic treatment. PLoS ONE 2009, 4, e5554.
94. Dapp, M.J.; Holtz, C.M.; Mansky, L.M. Concomitant lethal mutagenesis of human immunodeficiency virus type 1. J. Mol. Biol. 2012, 419, 158-170.
95. Torella, J.P.; Chait, R.; Kishony, R. Optimal drug synergy in antimicrobial treatments. PLoS computational biology 2010, 6, e1000796.
96. Pasquato, A.; Rochat, C.; Burri, D.J.; Pasqual, G.; de la Torre, J.C.; Kunz, S. Evaluation of the anti-arenaviral activity of the subtilisin kexin isozyme-1/site-1 protease inhibitor PF-429242. Virology 2012, 423, 14-22.
97. Kolokoltsov, A.A.; Adhikary, S.; Garver, J.; Johnson, L.; Davey, R.A.; Vela, E.M. Inhibition of Lassa virus and Ebola virus infection in host cells treated with the kinase inhibitors genistein and tyrphostin. Arch. Virol. 2012, 157, 121-127.
98. Lee, A.M.; Pasquato, A.; Kunz, S. Novel approaches in anti-arenaviral drug development. Virology 2011, 411, 163-169.
99. Narayanan, A.; Bailey, C.; Kashanchi, F.; Kehn-Hall, K. Developments in antivirals against influenza, smallpox and hemorrhagic fever viruses. Expert. Opin. Investig. Drugs 2011, 20, 239-254.
100. Neuman, B.W.; Bederka, L.H.; Stein, D.A.; Ting, J.P.; Moulton, H.M.; Buchmeier, M.J. Development of peptide-conjugated morpholino oligomers as pan-arenavirus inhibitors. Antimicrob. Agents Chemother. 2011, 55, 4631-4638.
101. Urata, S.; Yun, N.; Pasquato, A.; Paessler, S.; Kunz, S.; de la Torre, J.C. Antiviral activity of a small-molecule inhibitor of arenavirus glycoprotein processing by the cellular site 1 protease. J. Virol. 2011, 85, 795-803.
102. Eigen, M. Self-organization of matter and the evolution of biological macromolecules. Naturwissenschaften. 1971, 58, 465-523.